Navigation Links
VisualSonics to Sell Mauna Kea Technologies' Cellvizio(R) LAB on a Worldwide Basis to Animal Imaging Market
Date:3/31/2009

PARIS and TORONTO, March 31 /PRNewswire/ - Mauna Kea Technologies and VisualSonics today announced that they have entered an exclusive distribution agreement through which VisualSonics will market and sell Cellvizio LAB high resolution in vivo imaging systems to pre-clinical researchers on a worldwide basis.

Cellvizio LAB provides researchers with a new way to understand physiological phenomena at the cellular and sub-cellular levels in situ in animal subjects. For the first time, pre-clinical researchers are able to easily capture, analyze and compare smooth-motion video sequences of a wide array of cellular level characteristics and events, in real-time, without disturbing the natural environment in which they take place.

Cellvizio LAB is currently used by world-leading neuroscience research institutions in various applications including neurological research of the deep brain and peripheral nerves, especially in the research of degenerative diseases such as Alzheimer's and Parkinson's, where it offers a unique capability to couple in vivo and in situ observations of neuronal activity on freely moving animals with behavioral studies. The minimal invasiveness of Cellvizio LAB and its adaptability to longitudinal studies make it also a key-element for research fields such as cancer, stem cell and gene delivery research. As a new molecular imaging technique, Cellvizio LAB can help monitor the interactions and effects of new molecules and new potential drug vectors non-invasively. Cellvizio LAB can also be used as high-throughput screening technique for mutant line maintenance.

"VisualSonics has a great track record in introducing ground-breaking imaging solutions to the animal imaging market and is thus an ideal partner to bring Cellvizio LAB to top researchers working to continue to unlock physiological discoveries that have a strong impact on science and medicine," said Sacha Loiseau, President, CEO and Founder of Mauna Kea Technologies. "We're confident VisualSonics will greatly develop and expand the Cellvizio footprint in the field of animal imaging, while we continue to focus our efforts on making Cellvizio an indispensable tool for clinical gastroenterology procedures."

"With the Cellvizio system, we can offer researchers more in vivo imaging platforms: our existing family of high frequency ultrasound and now the Cellvizio optical microscopy" said Tom Little, CEO of VisualSonics. "The ability to see and monitor an animal's internal physiological processes at the cellular level helps researchers gain new understanding of the root causes of disease and disorders. Cellvizio LAB's real-time, microscopic, imaging of living cells truly compliments our flagship Vevo(R) high-resolution, ultrasound-based imaging platform. The Vevo(R) can also provide accurate in vivo image guidance of the Cellvizio LAB optical miniprobes making this combination unique to explore life sciences at multiple scales.

About VisualSonics

VisualSonics is the world's leading developer of high-resolution, ultrasound-based, in vivo micro-imaging systems designed specifically for non-invasive preclinical research. The company's enabling technology allows researchers at the world's most prestigious pharmaceutical and biotechnology companies, hospitals and universities to conduct research in cardiovascular, cancer, and developmental biology areas. The technology supports applications that include genetic research, phenotypic studies and drug development. VisualSonics platforms combine high-resolution, real time in vivo imaging at reasonable cost with ease-of-use and quantifiable results. More information on VisualSonics can be found at www.visualsonics.com.

About Mauna Kea Technologies

Mauna Kea Technologies, a French company with a multi-disciplinary scientific approach, has developed Cellvizio, a probe-based Confocal Laser Endomicroscopy (pCLE) system that makes dynamic imaging of life at the cellular level a reality. The cellvizio.net scientific knowledge interactive database is enabling an international community of leading scientists and physicians to share their ground-breaking work based on Cellvizio in gastroenterology and various fields of science and medicine. Mauna Kea Technologies is backed by leading life science investors which include The Psilos Group, Seventure and Creadev. For more information about Mauna Kea Technologies, visit www.maunakeatech.com.


'/>"/>
SOURCE VisualSonics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. VisualSonics and Seno Medical Instruments Sign Exclusive Opto-Accoustic Licensing Agreement for Preclinical Research
2. Oxford Finance Corporation and Comerica Bank Provide $15 Million Loan Facility to VisualSonics Inc.
3. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
4. Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company
5. Frost & Sullivan Recognizes Life Technologies for Excellence in the Life Science Research Tools Industry
6. Frost & Sullivan Recognizes Excellence in Medical Technologies & Life Sciences
7. Solos Endoscopy, Inc. Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies, Inc.
8. Venter Institute Launches the J. Robert Beyster and Life Technologies 2009-2010 Research Voyage of the Sorcerer II Expedition
9. RainDance Technologies Reviews Opportunities for Growth at Cowen Health Care Conference
10. Frost & Sullivan to Present the 2009 Excellence in Medical Technologies & Life Sciences Awards
11. Varian Medical Systems to Exhibit X-ray and CT Technologies for Non-Destructive Testing at the Upcoming ASNT 18th Annual Spring Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology:
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, Biometrics & ... & Other Service  The latest report from ... of the global Border Security market . Visiongain ... billion in 2016. Now: In November 2015 ... and hardware technologies for advanced video surveillance. ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):